RESEARKA

Mechanistically, aspirin's proposed anti-inflammatory action via cyclooxygenase inhibition aligns with pathways implicated in aging, such as the resolution of neutrophilic inflammation (Lu 2026). However, human evidence for this specific mechanism in a geroprotective context is sparse. One observational study on long-term anakinra therapy in Schnitzler syndrome reported remission of systemic inflammation, with p-values < 0.05 and < 0.01 for key biomarkers, but this targeted biologic therapy is not analogous to aspirin (Sikora 2026). A systematic review on lupus nephritis further highlights that tubulointerstitial inflammation is a critical determinant of renal function decline, emphasizing inflammation's broad pathological role (Donato 2026). Thus, while the mechanistic substrate linking aspirin to inflammation resolution exists, direct clinical geroprotection data are absent from this corpus.

Citation Support

• source_1 Flensted-Jensen 2025
• source_2 Saeed 2026
• source_3 Zhu 2026
• source_4 Navarese 2026
• source_5 Yan 2024